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Abstract: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system 
and leading cause of disability in young adults. Vision impairment is a common component of 
disability for this population of patients. Injury to the optic nerve, brainstem, and cerebellum 
leads to characteristic syndromes affecting both the afferent and efferent visual pathways. The 
objective of this review is to summarize the spectrum of eye disorders in patients with MS, their 
natural history, and current strategies for diagnosis and management. We emphasize the most 
common disorders including optic neuritis and internuclear ophthalmoparesis and include new 
techniques, such as optical coherence tomography, which promise to better our understanding 
of MS and its effects on the visual system.
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Introduction
Approximately 300,000 individuals in the United States are affected by multiple 
sclerosis (MS).1–4 The national economic burden of this disease has been estimated to 
be US $6.8 billion yearly and the total lifetime cost per case to be US $2.2   million.5 
Visual dysfunction is frequent and often irreversible. Afferent pregeniculate visual 
pathways (retina, optic nerves, chiasm, and tracts) are targets of inflammation, 
demyelination, and axonal degeneration (Panel 1). Nearly half of the MS patients 
develop optic neuritis (ON).6 It is the heralding event in 15%–20% of patients.6 
However, patients without a clinical history of ON also exhibit poor visual func-
tion, including worse scores on low-contrast acuity and color-sensitivity testing, 
when compared with age-matched controls.7,8 With the advent of newer technology, 
structural information about optic nerve disease is attainable, and MS patients with 
and without a history of ON demonstrate loss of axons in the retinal nerve fiber 
layer (RNFL).9–12
Injury is also common in the brainstem and cerebellum, generating efferent pathway 
deficits. Common ocular motor findings include internuclear ophthalmoparesis (INO), 
saccadic dysmetria, and nystagmus. Also found are skew deviation, abnormalities of 
smooth pursuit, and various nuclear and fascicular lesions. After careful bedside neuro-
ophthalmologic examination, these disorders can be readily identified. Corresponding 
lesions are often visible on magnetic resonance imaging (MRI).
The principal objective of this review is to provide a framework for understanding 
both the afferent and efferent visual disorders in MS and outline the current strategies 
for management of these syndromes.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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The afferent visual system in MS
Acute demyelinating ON
Clinical presentation
ON refers to the inflammation of the optic nerve. Although 
the differential diagnosis is broad and includes infectious, 
ischemic, and autoimmune disorders, the most common form, 
acute demyelinating ON, is best known for its association 
with MS. It is more prevalent in young patients and in wom-
en.13 The Optic Neuritis Treatment Trial (ONTT), the largest 
and most comprehensive study of this disease, followed 
an initial cohort of 457 patients for 10 years and provided 
important data on the natural history and visual outcomes of 
ON cases and the effects of high-dose steroids.14–19
The diagnosis of ON is primarily clinical based on 
history and examination.20 Patients report acute to subacute 
vision loss, color desaturation (in particular red color), and 
in the ONTT, 92% of patients reported pain with eye move-
ments.13 Vision loss is typically monocular and progresses 
over hours to days; worsening beyond 1–2 weeks is atypical 
and suggestive of other causes of optic   neuropathy.15 Simi-
larly, it is expected that some recovery will occur within 
1 month of symptom onset. Failure to see improvement 
in this time frame, the presence of no light perception at 
onset, and lack of eye pain suggest other diagnoses and are 
associated with lower risk for developing MS.21,22 A single 
episode of ON with no history of other ophthalmologic or 
neurological events can be described as a clinically isolated 
syndrome (CIS).
Afferent neuro-ophthalmologic examination
The afferent eye examination begins with acuity testing. 
Prescription lenses or pinhole correction are used to correct 
  refractive error. Distance, near card, or both are measured for 
normal contrast levels. As discussed below, further evalua-
tion with low-contrast charts may reveal more subtle visual 
  dysfunction. Visual fields are tested to confrontation for each eye 
separately and together. Static and dynamic finger   recognition 
may be helpful. Red–green color desaturation is a common 
feature in ON and may be detected by the patient’s description 
of “washed out” appearance of red objects; however, it is usu-
ally formally tested with Ishihara pseudoisochromatic plates or 
Farnsworth–Munsell 100 hue test, as done in the ONTT.
Pupils are evaluated for shape, position, anisocoria, and 
reactivity. In addition, detection of a relative afferent pupil-
lary defect (RAPD) is suggestive of an optic neuropathy. 
Absence of an RAPD in the setting of visual loss may reflect 
retinal disease or bilateral optic nerve disease. Funduscopic 
examination reveals normal   appearing discs in most of the 
cases; these patients are said to have retrobulbar ON. In 
the ONTT, optic disc swelling was present in 35.3% of the 
patients (Figure 1).13 Marked swelling, retinal hemorrhages, 
A
B
Figure 1 The optic disc in acute demyelinating optic neuritis. Most patients have 
retrobulbar optic neuritis, and the optic disc appears normal (A). In one-third of the 
patients, disc swelling is present and is typically diffuse and mild (B).13
Copyright  ©  2006,  Massachusetts  Medical  Society.  Adapted  with  permission  from 
Balcer LJ. Optic neuritis. N Engl J Med. 2006;354:1273–1280. Liu GT, Volpe NJ, Galetta 
SL.  Neuro-Opthalmology:  Diagnosis  and  Management.  1st  ed.  Philadelphia,  PA:  WB 
Saunders Company; 2001.
Panel 1 Afferent neuro-ophthalmologic disorders in MS
Acute demyelinating optic neuritis
   Painful acute to subacute (hours to days) onset of visual loss typically 
characterized by central field deficit, dyschromatopsia, and recovery 
beginning within 2–4 weeks. Two-thirds will have normal funduscopic 
exam.
Subclinical visual loss in MS
   Functional loss as seen in low-contrast letter acuity testing; structural 
retinal nerve fiber loss as measured by techniques, such as OCT
Chiasmal and postchiasmal visual field defects
   Homonymous field deficits are rare and are typically associated with 
large demyelinating lesions.
Ocular inflammatory disorders
  Anterior uveitis (granulomatous, nongranulomatous) 
  Pars planitis (intermediate uveitis) 
  Retinal periphlebitisClinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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to be robust across multiple   testing contexts.30,31 The revised 
criteria for diagnosing NMO are the presence of 2 of the 
following 3 findings – LETM (defined as $3 vertebral seg-
ments), onset brain MRI nondiagnostic for MS, or NMO-IgG 
seropositivity.28 Antibody positivity may help determine 
the likelihood of recurrent disease and guide the decision 
to treat with immunosuppression following an episode of 
ON or recurrent ON.30,32–34 Although large treatment trial 
data are not available, therapies studied and shown to have 
beneficial effects include plasma exchange, rituximab, and 
azothiaprine.35–39
Other causes of inflammatory or toxic metabolic optic 
neuropathy may mimic acute demyelinating disease.20 
Depending on the clinical assessment and presence of atypi-
cal features, serologic or cerebrospinal fluid (CSF) testing for 
sarcoidosis, systemic lupus and other vasculitides, thyroid 
disease, syphilis, nutritional deficiencies, Lyme disease, 
Bartonella hensalae infection (cat scratch neuroretinitis), and 
paraneoplastic disorders may be warranted.   Consideration 
should also be given to the newly recognized entity, chronic 
relapsing inflammatory optic neuropathy (CRION), a granu-
lomatous optic neuropathy.40
Vision testing
Although the diagnosis of ON is made clinically, additional 
testing of vision function can be used to support the diagnosis 
and further characterize the patient’s deficits. In the ONTT, 
visual outcome measures included formal visual field testing 
(Humphrey 30-2® program) and contrast sensitivity (Pelli-
Robson® chart). Visual field deficits were found in 97.5% of 
patients.13 Central scotomas were common but other patterns, 
including diffuse and focal defects, were seen. Contrast-
sensitivity (minimum contrast level at which patients can 
see letter of single large size) abnormalities were seen in 
98.2% of patients.41
Low-contrast letter acuity charts, which have a format 
similar to Early Treatment Diabetic Retinopathy Study 
(ETDRS) charts with light gray letters of progressively 
smaller size with varying contrast on white background, 
have also been used to detect visual dysfunction in patients 
with ON and MS.7–9,42 Abnormalities can be detected even 
in those patients with 20/20 vision measured by standard 
Snellen® charts.
Visual evoked potentials (VEPs) can be helpful in pro-
viding data to support the diagnosis of acute demyelinating 
disease, ON, or MS. Prolonged latencies are consistent with 
demyelinating disease and are present in over two-thirds of 
patients with ON.43–45 Multifocal VEPs can be more sensitive 
and exudates are atypical, which suggest an alternative diag-
nosis and predict a lower risk of developing MS.21,22
Differential diagnosis
Acute demyelinating ON must be differentiated from other 
causes of optic neuropathy. As described earlier, lack of 
eye pain, severe initial vision loss, marked swelling, and 
retinal hemorrhages may indicate an alternative diagnosis 
of anterior ischemic optic neuropathy (AION, Table 1).23 
AION usually occurs in older patients. Compared with 
ON, the vision loss is often sudden in onset, altitudinal, and 
more likely to persist, with longer time to recovery.24 When 
vision loss progresses beyond 10–14 days, Leber hereditary 
optic neuropathy, a mitochondrial disorder leading to the 
  degeneration of the optic nerve, may need to be considered, 
along with   compressive optic neuropathy.
Bilateral ON or ON coupled with longitudinally exten-
sive transverse myelitis (LETM) is suggestive of neuromy-
elitis optica (NMO), a disorder associated with aquaporin-4 
(a water channel present in glial cells) antibodies.25–27 Testing 
for NMO-IgG should be considered in those patients with 
the features described earlier, recurrent ON, or brain MRIs 
atypical for MS.27 In 1 study, in which patients were identi-
fied by having been tested for NMO-IgG, seropositivity 
was shown to be 76% sensitive and 94% specific for 
NMO.28 A prospective study of 114 patients with ON in 
various clinical contexts demonstrated that 56% of those 
with   clinical NMO had positive serum antibodies.29 In 
  noncausasions or while using different detection methods, 
the sensitivity of testing may vary, but specificity appears 
Table 1 Clinical features and primary differential diagnosis of 
acute demyelinating optic neuritis
Acute demyelinating 
optic neuritis
Anterior ischemic 
optic neuropathy
Age, y 20–50 .50
Pain 92%, exacerbated by eye 
movementsa
Uncommon
Onset Progression over hours 
to days
Sudden onset, often 
recognized upon 
awakening
Disc swelling Present in only one-third 
of patients, remainder are 
retrobulbara
Common, sectoral, 
often with hemorrhages
Field defect Typically central, but 
variable
Typically altitudinal
Recovery Begins within 2–4 weeks, 
overall good prognosis
Over months, in 
approximately 40%b
Notes: a From  the  optic  neuritis  treatment  trial  (ONTT);13  bIschemic  optic 
neuropathy decompression trial.24 
Copyright © 2006, Massachusetts Medical Society. Adapted with permission from 
Balcer LJ. Optic neuritis. N Engl J Med. 2006;354:1273–1280. Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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It is recommended in every patient to pursue brain MRI 
(Figure 2A), as the presence of periventricular white matter 
lesions is associated with higher risk in first event cases 
of developing a second demyelinating event consistent 
with MS and may warrant early treatment as discussed 
below. In the ONTT follow-up at 10 years, 56% of ON 
patients with 1 or more T2 lesions on MRI had developed 
MS compared with 22% of those with normal scans.21 
Brain lesions are common and are seen in 50%–70% of 
patients.50,51 In 1 study, spinal cord T2 lesions were seen in 
27% of patients.50
Artifacts can limit MRI studies in ON and MS. Fat- and 
CSF-suppressed imaging, diffusion tensor and magnetiza-
tion transfer imaging, and spectral presaturation inversion 
recovery–fluid-attenuated inversion recovery (SPIR–FLAIR) 
imaging promise more sensitivity and detailed structural 
information of not only ON but also of long-term atrophy 
and changes in the optic nerve.49,52,53
Optical coherence tomography
New advances in optical coherence tomography (OCT) have 
also allowed for direct structural assessment of axonal loss 
associated with ON.10,54 OCT, an optical analog of ultrasound 
B-mode imaging, provides cross-sectional or 3-dimensional 
images of the internal retinal structure.11,55,56 Measurements 
of the thickness of RNFL, ganglion cell axons, can be readily 
obtained. Studies have demonstrated RNFL thinning in eyes 
with a history of ON; in 1 study, reductions in RNFL thick-
ness occurred in 74% of patients, typically within 3–6 months 
of the acute episode.57,58 Decreases in RNFL thickness 
have been correlated with measures of visual dysfunction, 
such as low-contrast acuity and with brain atrophy on MRI 
scans.9,59–61 Although currently used primarily in the research 
setting, longitudinal OCT measurements have the potential 
to elucidate the natural history of axonal loss in ON and MS 
patients, as well as to provide a biomarker for the neuropro-
tective effects of current and future therapies. Studies of other 
methods for measuring the axonal layer, including scanning 
laser polarimetry, may also generate structural biomarkers 
for studying progression in MS.10,12
Natural history
In cases of typical ON, visual recovery begins within 
2–3 weeks. The natural history of the disease is likely best 
described by the course of patients in the placebo arm of the 
ONTT. With median baseline acuity of affected eyes mea-
sured to be 20/60, vision improved to 20/25 by day 15 and 
to 20/20 at 1 month of follow-up.62 In the 10-year follow-up 
A
B
Figure 2 Magnetic resonance imaging (MRI) in multiple sclerosis (MS) and optic 
neuritis  (ON).  Multiple  periventricular  T2-hyperintense  lesions  are  shown  in  a   
T2-weighted axial image of the brain in a patient with MS (A). T1-weighted gadolinium-
enhanced axial image of the orbits demonstrates diffuse enhancement of the right 
optic nerve in a patient with acute demyelinating ON (B).
Copyright © 2006, Massachusetts Medical Society. Adapted with permission from 
Balcer LJ. Optic neuritis. N Engl J Med. 2006;354:1273–1280. Liu GT, Volpe NJ, 
Galetta SL. Neuro-Opthalmology: Diagnosis and Management. 1st ed. Philadelphia, PA: 
WB Saunders Company; 2001.
and specific; they can be useful in distinguishing optic nerve 
and retinal disease or for detecting subclinical dysfunction, 
but are not widely available for clinical use.43,46,47
Magnetic resonance imaging
MRI of the optic nerves is abnormal in approximately 90% 
of clinical cases (Figure 2B) and can be helpful in diagnosis 
under certain clinical circumstances, as in differentiating 
acute demyelinating ON and AION.48 Gadolinium enhance-
ment is frequent and has been shown to be associated with 
clinical findings such as decreased acuity, RAPD, and 
abnormal VEPs.49Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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of 319 patients from the ONTT, visual acuity (treated and 
untreated) in the affected eye was equal to or better than 
20/20 in 74%, 20/25 to 20/40 in 18%, 20/50 to 20/200 in 
5%, and 20/200 in 3%.19 However, even with recovery of 
visual acuity, self-reported visual functioning as measured 
by the National Eye Institute Visual Functioning Question-
naire (NEI-VFQ-25) can remain affected. Evidence of optic 
atrophy can be seen weeks following the acute event.19 
  Contrast sensitivity and visual fields were abnormal in 33% 
and 27% of affected eyes, respectively (compared with 98.2% 
and 97.5% at baseline as mentioned earlier), in the 10-year 
follow-up of the ONTT.19
Of interest in the natural history of ON is the rate of 
recurrent ON and the development of MS. Recurrence 
of ON in the 10-year follow-up of the ONTT was 31% 
for the placebo group (48% for those with MS and 24% 
of those without MS).19 Risk for developing MS in the 
treatment and placebo arms followed for 10–13 years was 
38%.22 As discussed earlier, the risk was higher for those 
with brain MRI lesions and lower (close to zero) for those 
patients with atypical clinical features, such as severe optic 
disc swelling, peripapillary hemorrhages, and absence of 
eye pain.21,22
Treatment
Short-term therapy with corticosteroids
High-dose intravenous (IV) methylprednisolone hastens 
recovery of visual acuity and other visual function tests over 
a 2-year follow-up, but does not affect the long-term visual 
outcomes of patients with ON or their 10-year risk of devel-
oping MS. In the ONTT, patients were randomized within 
8 days of onset of symptoms to 1 of 3 treatment groups: 
(1) IV   methylprednisolone 250 mg every 6 hours for 3 days, 
followed by oral prednisone 1 mg/kg/d for 11 days with a 
4-day taper, (2) oral prednisone 1 mg/kg/d for 14 days fol-
lowed by 4-day taper, or (3) oral placebo.15 Treatment with IV 
steroids was associated with a more rapid recovery of visual 
field deficits and contrast sensitivity, particularly within the 
first 15 days, and differences in recovery for these para  meters 
remained significant at 6-month follow-up.15 For visual 
acuity, there was no difference between treatment groups at 
6 months. At 1 year of follow-up, there were no significant 
differences for any measure of visual function.17
The rate of development of MS, then defined as a second 
clinical demyelinating event, after 2 years of follow-up was 
7.5% in the IV methylprednisolone group, 14.7% in the oral 
prednisone group, and 16.7% in the placebo arm. These data 
suggested an early protective effect in the development of 
clinically definite MS (CDMS).63 However, this effect did 
not persist in further follow-up evaluations.
Similar studies have also shown potential early but no 
  significant long-term benefits for corticosteroid therapy 
in ON. A randomized study in Japan compared IV methyl-
prednisolone with oral methylcobalamine and demonstrated 
quicker recovery of visual acuity, visual fields, contrast sen-
sitivity, and color vision but no long-term effect on visual 
outcomes.64 A meta-analysis of 12 randomized controlled 
trials in ON and MS also showed that corticosteroid use 
appeared to hasten recovery within 1 month of symptom 
onset, but significant benefits were not observed after 1 year 
of follow-up.65
Another outcome of the ONTT was an increased rate of 
recurrent ON in the oral prednisone group compared with the 
IV methylprednisolone and the placebo groups. At 5 years of 
follow-up, the oral prednisone group had a rate of recurrence 
of 41% compared with 25% for the IV methylprednisolone 
and placebo groups.66 This increased risk did not persist at 
10 years of follow-up.19 This result has discouraged the use 
of oral prednisone for the acute treatment of ON. Higher 
doses of oral steroids (500 mg methylprednisolone daily for 
5 days) in a small prospective trial did not show increased 
risk of recurrent ON within 1 year.67
Long-term therapy with immunomodulatory agents
In patients with a first event of ON, early treatment with 
disease-modifying therapy (Table 2), interferon, or glati-
ramer acetate may delay the onset of a second clinical 
demyelinating event and the development of new T2 lesions 
or gadolinium enhancement. Three randomized trials of 
patients with first demyelinating events, including ON, have 
shown benefit for early treatment with interferon β-1a and 
interferon β-1b. An additional trial recently showed similar 
results for glatiramer acetate.
The Controlled High-Risk Subjects Avonex Multiple 
Sclerosis Prevention Study (CHAMPS) was a double–
blinded, randomized clinical trial that included 383 patients 
with acute ON or other first demyelinating event.68 The 
patients were considered high risk for MS based on MRI cri-
teria of 2 or more white matter lesions. All patients received 
1 g of IV methylprednisolone daily followed by an oral 
prednisone taper. They were then randomly assigned within 
27 days to receive weekly injections of 30 µg intramuscular 
interferon β-1a (Avonex®) or placebo injections. The trial 
was stopped early after a preplanned efficacy analysis. 
The trial’s 2 primary end points, development of CDMS 
and changes on MRI, demonstrated benefit for interferon Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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therapy. Patients receiving intramuscular interferon β-1a 
had a 44% reduction in the 3-year risk of CDMS (P = 0.02) 
and fewer new and enhancing lesions on MRI.68 In subgroup 
analyses, the beneficial effect was present for presentations 
of ON, as well as for brainstem–cerebellar and spinal cord 
syndromes.69,70 The extension study, Controlled High-Risk 
Avonex Multiple Sclerosis Prevention Study in Ongoing 
Neurological Surveillance (CHAMPIONS), demonstrated 
that patients who received the early interferon treatment 
(those initially randomized to the active treatment group) 
had persistently lower risk of developing MS at 5 years of 
follow-up (21%) compared with those who started therapy 
once efficacy was established at 2–3 years of follow-up in 
open-label extension (35%).71
The Early Treatment of Multiple Sclerosis (ETOMS) 
study also showed that interferon β-1a reduces risk of devel-
oping MS over 2 years after a first demyelinating event.72 
In this trial, 308 patients were randomized to weekly 22 µg 
subcutaneous interferon β-1a (Rebif®) or placebo within 
3 months of symptom onset. Over one-third of patients 
had evidence of 2 or more white matter lesions on MRI at 
presentation, and most of the patients had received steroids 
before initiation of injections. Treated patients had a risk 
of 34% of developing MS in the 2-year period vs 45% for 
controls (P = 0.047). Another marker for benefit, the time 
for 30% of each cohort to develop MS was 569 days in the 
interferon group and 252 in the placebo group (P = 0.034). 
Annual relapse rate was also lower in the interferon group, 
0.33 vs 0.43 per year (P = 0.045), and disease burden by 
MRI was less.
The third trial, Betaferon/Betaseron in Newly emerging 
Multiple Sclerosis for Initial Treatment (BENEFIT) looked 
at another common injectable therapy for MS.73 Patients 
with acute demyelinating events (487, 80 with ON) were 
Table 2 Treatment choices for optic neuritis or other first demyelinating event in patients at risk for multiple sclerosis
Trial evidence Medication (standard dosage) Contraindications/potential 
side effects
Potential benefits
Short-term therapy
Optic neuritis treatment trial 
(ONTT, n = 457)
Intravenous methylprednisolone 
(250 mg every 6 h for 3 d) + oral 
taper
Contraindications: systemic 
infection, immune deficiency, 
severe hypertension, or 
diabetes mellitus; Side effects: 
insomnia, mood disturbance, 
gastric irritation, hyperglycemia, 
hypertension
1.   Faster recovery of visual function;   long-
term visual outcome not affected
2.   Reduced rate of MS development within 
the first 2 y
3.   Oral prednisone at dose of 1 mg/kg 
may increase the risk of recurrent optic 
neuritis and should be avoided.
Long-term therapy
Controlled high-risk subjects 
avonex MS prevention study 
(CHAMPS, n = 383)
Interferon β-1a (Avonex, 30 µg 
intramuscularly weekly)
Contraindications: pregnancy 
category C, hypersensitivity to 
interferon β or human albumin; 
Side effects: flu-like symptoms 
(fever, myalgias), depression, 
anemia, hepatic dysfunction
1.   Reduction (44%, P = 0.02) in the 3-y risk 
of developing CDMS
2.   Fewer new and enhancing lesions on MRI
Early treatment of MS study 
(ETOMS, n = 308)
Interferon β-1a (Rebif, 22 µg 
subcutaneously weekly)a
Contraindications: pregnancy 
category C, hypersensitivity to 
interferon β or human albumin; 
Side effects: flu-like symptoms 
(fever, myalgias), depression, 
anemia, hepatic dysfunction
1.   Lower risk of developing CDMS over  
2 y (34% vs 45% placebo, P = 0.047)
2.   Decreased annual relapse rate (0.33 
vs 0.43, P = 0.045)
3. Fewer lesions on MRI
Betaferon/Betaseron in 
newly emerging MS for initial 
treatment (BENEFIT, n = 468)
Interferon β-1b (Betaseron,  
250 µg subcutaneously every 
other day)
Contraindications: pregnancy 
category C, hypersensitivity to 
interferon β or human albumin; 
Side effects: flu-like symptoms 
(fever, myalgias), depression, 
anemia, hepatic dysfunction
1.   Reduced 2-y risk of developing CDMS 
by the Poser (28% vs 45% placebo, 
P , 0.0001) and McDonald (69% vs 85% 
placebo) criteria
2. Fewer lesions on MRI
Effect of glatiramer acetate 
on conversion to clinically 
definite multiple sclerosis 
(PreCISe, n = 481)
Glatiramer acetate (Copaxone,  
20 mg subcutaneously daily)
Contraindications: pregnancy 
category B; Side effects: 
injection site reaction, rash, 
vasodilation, dyspnea, chest pain
1.   Decreased risk of developing CDMS 
compared with placebo by 45% 
(P , 0.0005)
2. Fewer lesions on MRI
Notes: aETOMS used weekly 22 µg Rebif, while standard therapy for MS is 22 or 44 µg 3 times a week. 
Adapted with permission from Burkholder et al.157
Abbreviations: MS, multiple sclerosis; CDMS, clinically definite multiple sclerosis; MRI, magnetic resonance imaging.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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randomized to 250 µg of subcutaneous interferon β-1b 
(Betaseron®) or placebo. Development of CDMS by the 
Poser criteria was 28% in the treatment group vs 45% in the 
placebo group (P , 0.0001) and by the newer McDonald 
criteria, including MRI parameters for lesions in time and 
space, was 69 vs 85%, respectively.73–75 Patients on interferon 
also had significantly fewer lesions on brain MRI.
The effect of glatiramer acetate (Copaxone®) on the 
development of second demyelinating events after a CIS was 
addressed by the PreCISe trial. Patients with CIS and 2 or 
more T2-weighted brain lesions were assigned to 20 mg sub-
cutaneous glatiramer acetate daily vs placebo for 36 months.76 
Use of the drug reduced the risk of developing CDMS by 
45% compared with placebo.76
Summary
In patients with ON and high risk of MS, defined as 2 or 
more white matter lesions on brain MRI and lack of atypi-
cal clinical features, we recommend treatment in the acute 
setting with IV methylprednisolone followed by disease 
modifying therapy. Discussion with the patient about 
his or her risk of MS is important in this setting. Even in 
those patients without the evidence of other MRI lesions, 
it is appropriate to follow them with MRI scans for future 
development of white matter lesions. IV steroids may also 
be recommended in this group to expedite recovery of 
visual function.
Visual loss in absence of acute  
clinical ON
Even in patients without history of acute clinical ON, MS 
is associated with visual dysfunction. Low-contrast letter 
acuity charts have been used to detect clinically subtle 
visual dysfunction in MS, even among patients with 20/20 
or better high-contrast visual acuity and no history of 
acute ON.7,8 Use of low-contrast letter acuity charts and 
the Pelli-Robson contrast-sensitivity chart can distinguish 
MS eyes from controls to a degree better than high-contrast 
visual acuity testing.42 OCT studies demonstrate subclinical 
RNFL thinning in MS eyes, even among those without a 
history of acute ON. While the greatest reductions in RNFL 
thickness are seen in eyes with history of ON, non-ON 
eyes of MS patients show decreases in RNFL thickness 
compared with disease-free controls.9,77 RNFL thinning 
in MS has been shown to correlate with MRI measures 
of lesion volume and normalized brain volumes, for 
example, T1- and T2-lesion volume and normalized gray 
matter volume (relationship to normalized white matter 
volume is less clear) and with losses of low-contrast   acuity 
over time.60,78–80
Other afferent disorders in MS
Disorders of the afferent visual system in MS may encompass 
structures beyond the optic nerve, including chiasmal and 
postchiasmal visual field deficits, or may involve diseases of 
ocular inflammation (Panel 1). Symptomatic homonymous 
field deficits are rare, but with screening, unrecognized 
defects may be found.81 In the ONTT, 13.2% of patients had 
evidence of a chiasmal or retrochiasmal deficit upon serial 
screening, 5.1% of which were bitemporal and 8.9% were 
homonymous.82 In 1 study of 18 patients with retrochiasmal 
field deficits, lesions were found on MRI in the posterior optic 
radiations, the optic tract, lateral geniculate nucleus, and the 
posterior limb of the internal capsule; all of the lesions were 
unusually large, a characteristic feature considered necessary 
to observe a homonymous deficit in this disease.83
Ocular inflammation may be seen in patients with MS. 
Types include anterior uveitis, pars planitis (intermediate 
uveitis), and retinal periphlebitis. Uveitis is 10 times more 
common in MS patients than in the general population, but 
it is a rare complication and often unrecognized.84,85 In a 
study of 16 MS patients with uveitis, Zein et al86 reported 
that 94% of those cases were bilateral and 81% were pars 
planitis. Half of the cases were previously diagnosed with 
MS; in 25% of the cases, the diagnosis of uveitis preceded 
the diagnosis of MS; and in 19% of the cases, the diagnoses 
were made concomitantly.86
Anterior uveitis, including granulomatous and non-
granulomatous forms, arises uncommonly in patients 
with known MS, but may manifest before diagnosis.85 In 
cases of granulomatous disease, other etiologies must be 
excluded, including sarcoidosis, tuberculosis, syphilis, 
Lyme   disease, rheumatologic disorders, Behcet’s disease, 
and Vogt–Koyanagi–Harada syndrome. Despite the rarity 
of isolated anterior uveitis in MS, it is worth considering 
that the agents used in other inflammatory processes, such 
as tumor necrosis   factor α, may be ineffective or detrimental 
in   demyelinating disease.87–89
Pars planitis, an idiopathic form of intermediate uveitis, 
is characterized by intravitreal inflammation and pars plana 
and peripheral retinal exudates.90 It may have no symptoms 
or be associated with vision loss from complications, includ-
ing cataracts, epiretinal membrane formation, or macular 
edema. In a prospective study of 21 patients with pars 
planitis, 47.6% were found to have demyelinating lesions 
on MRI, and relapsing remitting MS was diagnosed in Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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33.3%.90 Another small study found MS in 16% of patients 
with pars planitis and found an association between human 
leukocyte antigen-DR15 (HLA-DR15) and this form of 
uveitis (odds ratio [OR] = 2.86; 95% confidence interval [CI], 
1.42–5.78, P = 0.004).91 The latter association between pars 
planitis and HLA-DR2 allelic subtypes has been observed 
by other groups as well.92,93 Overall visual prognosis is 
generally good with most affected eyes retaining better than 
20/40 visual acuity.90,91 Treatment options include steroids, 
nonsteroidal anti-inflammatory agents, immunosuppressant 
therapy, cryotherapy, or vitrectomy.90 In pars planitis patients 
not previously diagnosed with MS, MRI studies should be 
considered to rule out demyelinating disease.
Cuffing of retinal veins by inflammatory cells causing 
whitish exudates, or retinal periphlebitis, is found in 5%–36% 
of patients with MS.94–97 Its presence is thought to be more 
common in active stages of the disease and its pathogenesis 
may share commonalities with perivenular inflammation 
in typical MS plaques.95,96,98,99 Retinal periphlebitis in MS 
is typically mild and may not have any clinical manifesta-
tions; more severe cases may be seen in disorders such as 
sarcoid, syphilis, toxoplasmosis, Eale disease, and idiopathic 
uveitis.100
The efferent visual system in MS
Discrete lesions in the ocular motor pathway result in classic 
efferent syndromes (Table 3). The most common of these are 
INO, saccadic dysmetria, nystagmus, and suppression of the 
vestibulo-ocular reflex (VOR).101,102 MRI studies, particularly 
proton density and T2 images, often show these lesions in the 
corresponding areas of the brainstem and cerebellum.103
The ocular motor examination
Careful bedside examination can reveal the common efferent 
disorders associated with MS.104 Components of the examina-
tion should include assessment of ocular alignment and motil-
ity. Alignment in the primary and the cardinal directions of 
gaze should be evaluated, and the presence of tropias, phorias, 
and head tilt determined. Ductions   (monocular motility) and 
versions (binocular motility) as well as Maddox rod measure-
ments or other assessment of diplopia should be performed. 
Saccades, brief eye movements from one point of fixation to 
another, should be assessed for latency, velocity, and accuracy 
and may reveal INO and ocular dysmetria due to cerebellar 
dysfunction, nystagmus, or gaze palsy. Smooth pursuit can be 
affected by inattention or broken into saccadic movements. 
Saccadic intrusions visible by external or funduscopic exami-
nation are also seen in MS and include square-wave jerks, 
oscillations, and ocular flutter or   opsoclonus. Various types 
of nystagmus and vestibular disorders are often observed, 
with the most common types summarized below. Evaluations, 
such as observation during eye movements, VOR testing, and 
head thrust, can help distinguish between the neuroanatomic 
possibilities.
Internuclear ophthalmoparesis
INO, characterized by limited or slow adduction of the 
ipsilateral eye on horizontal saccadic eye movements and 
usually accompanied by horizontal nystagmus in the con-
tralateral eye, INO is commonly associated with MS, and 
when seen in young undiagnosed patients, an INO should 
prompt a workup for demyelinating disease.102,105–107 Lesions 
of the medial longitudinal fasciculus (MLF), located in the 
dorsomedial pontine or midbrain tegmentum, cause INO. In 
a study of 58 patients with MS and INO, all had evidence of 
lesions in the MLF by proton density imaging.103 Etiologies of 
INO in a retrospective study of 65 patients included vascular 
(36.9%), MS (32.3%), and infectious disease (13.8%).105 
In half of these patients, the INO persisted after 1 year of 
follow-up. In 2005, Keane106 summarized 33 years of his 
clinical experience with INO and also noted approximately 
one-third of cases to be from stroke and one-third from MS. 
Although 87% of the stroke cases were unilateral, bilateral 
disease was more suggestive of MS.
About one-quarter of MS patients suffer from clinically 
diagnosed unilateral or bilateral INO.102,107 Symptoms may 
include blurred vision, diplopia, oscillopsia, loss of stere-
opsis, and reading fatigue. Convergence typically remains 
intact. Physician detection of INO is accurate in severe cases 
with decreased range of adduction, but in mild to moderate 
cases, only the velocity of adduction may be affected, and 
the diagnosis is often missed.108 In these patients, the use of 
infrared oculography may reveal the adduction deficit.108–110 
Thus, the prevalence of INO in MS patients is likely 
underestimated.
Nystagmus of the contralateral eye may be an adaptive 
process to compensate for the break in binocular fusion 
with the weak or slow adduction of the ipsilateral eye.111–113 
Other findings which may be associated with an INO include 
slowing of abduction, disturbance in vertical eye movement, 
and skew deviation.113 Slowing of abduction in the ipsilateral 
eye has been reported, particularly in cases of significant 
ophthalmoparesis and large MRI lesions, and it is thought 
to be related to defective relaxation of the dysfunctioning 
antagonist medial rectus.104,113–115 Vertical eye movement dis-
orders are associated with bilateral INO. The MLF carries the Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 3 Common efferent neuro-ophthalmologic disorders in MS
Abnormality Frequencya Localization Features Treatment References
INO 60%–68% MLF (Dorsomedial 
pontine or midbrain 
tegmentum)
Limited or slow 
adduction in ipsilateral 
eye on horizontal 
saccadic eye movements; 
horizontal nystagmus in 
contralateral eye
Steroids acutely 88, 103–118
Saccadic dysmetria 80%–91% Cerebellum, brainstem Overshoots, 
undershoots, directional 
dysmetria, ipsipulsion, 
contrapulsion
Steroids acutely 102–103, 105, 
119
Nystagmus 36%–65% (gaze-evoked) 
10%–18% (pendular and 
downbeat in central 
position)
Cerebellum, brainstem,  
vestibular apparatus
Gaze-evoked, pendular, 
upbeat, downbeat, 
multidirectional, rebound, 
vestibular, periodic 
alternating, occult (with 
ophthalmoscopy)
Gabapentin, 
memantine, baclofen, 
clonazepam, 3,4-
diaminopyridine, 
prisms, surgery
102–103, 
124–143
Saccadic intrusions n/a Brainstem (pause cell 
neurons), cerebellum
Inappropriate saccades 
including square-wave  
jerks, macro square-wave 
jerks, macrosaccadic 
oscillations, ocular 
flutter, opsoclonus, and 
microsaccadic flutter
Baclofen, 
anticonvulsants, 
memantine?
88, 105, 120–123
Smooth pursuit 
impairment
31%–75% Higher cortical pursuit 
system (parietal-
occipital-temporal 
junction)
Inability to maintain 
conjugate fixation on  
a moving target
None 102–103, 145
VOR impairment 36%–55% (75%)b Flocculus Inability to suppress 
the VOR; characteristic 
catch-up saccades when 
trying to fixate on  
a target moving with the 
head
None 102–103, 105, 
146, 147
Notes: aIn MS patients with abnormal eye movements;102,103 bIn a study of 20 patients with MS.146 
Abbreviations: MS, multiple sclerosis; MLF, medial longitudinal fasciculus; INO, internuclear ophthalmoparesis; VOR, vestibular ocular reflex.
myelinated fibers of the vertical pursuit, vertical   vestibular, 
and otolithic-mediated ocular movement   pathways. Patients 
with bilateral INO present with vertical and torsional 
  nystagmus, characteristic of vertical gaze-holding and verti-
cal VOR abnormalities, and altered optokinetic and pursuit 
responses.104,116,117 Skew deviation and supranuclear vertical 
ocular misalignment with binocular torsional deficits can 
occur with an INO. The higher eye is usually on the side of 
the MLF lesion.87,104,113
Disorders of fixation
Saccadic dysmetria, saccadic intrusions, and nystagmus are 
disorders of fixation seen in MS patients. Saccadic dysme-
tria is present in most of the MS patients with abnormal eye 
movements.101,102 Patients may exhibit overshoots (hyper-
metria), undershoots (hypometria), or directional dysmetria 
(vertical movements in a horizontal saccade). Lesions in the 
cerebellar vermis and posterior fastigial nuclei affect sac-
cadic accuracy. Hypometria may occur if the vermis alone 
is affected, and hypermetria may occur if deep nuclei are 
involved.104,118
Saccadic intrusions include square-wave jerks, inap-
propriate sudden movements away from and back to a point 
of fixation. There is an intersaccadic latency between these 
events. Macro square-wave jerks are similar to and fro 
intrusions but are larger in amplitude. Ocular flutter and 
opsoclonus are saccadic intrusions without interval latency. 
The former is characterized by back to back horizontal 
saccades, and the latter involves horizontal, vertical, and 
torsional   saccades.119 Microsaccadic flutter similarly has no 
intersaccadic latency, and when patients may report shim-
mering or wavy vision, ophthalmoscopy or eye-movement 
recordings are often required to make this rare diagnosis.120 
Saccadic intrusions result from lesions in the cerebellum 
and brainstem; pause cell (located in the pontine raphe) 
dysfunction has been implicated, and these disorders may Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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respond to anticonvulsants or baclofen.87,104,120 For various 
etiologies, a number of other agents have been tried, including 
methylphenidate, IV immunoglobulin, and clonazepam.121 
Memantine has also been used to improve saccadic intrusion 
frequency in 2 patients with hereditary ataxia.122
Dysfunction of gaze-holding mechanisms in the brain-
stem and cerebellum may lead to the drifting of the eyes away 
from a target followed by involuntary corrective saccades, 
defined as nystagmus. When symptomatic, the patient often 
experiences visual dysfunction and oscillopsia, a skipping 
of the visual environment. Many types of nystagmus may 
be seen in MS. Gaze-evoked nystagmus is seen in roughly 
one-third of MS patients and may be caused by lesions in the 
medial vestibular nucleus, nucleus prepositus hypoglossi, and 
flocculus.101,102,123 Pendular nystagmus, oscillations in which 
there is equal velocity in both directions, also occurs often 
relatively and can interfere with visual function.101,102,123–127 
Other forms of nystagmus reported in MS include upbeat, 
downbeat, rebound, multidirectional, periodic alternat-
ing, see-saw, dissociated, and vestibular.101,102,104,128–131 
Small studies have demonstrated successful treatment 
for nystagmus with baclofen, gabapentin, memantine, 
  clonazepam,   3,4-diaminopyridine, fampridine, prisms, and 
surgery.104,121,128,132–143
Other efferent disorders in MS
A variety of other efferent syndromes may be present in MS 
patients depending on the location of demyelinating lesions. 
Impairment of smooth pursuit is common and likely related 
to the disruption of higher cortical centers, including the 
parieto-occipital-temporal junction.101,102,144 Patients with 
abnormal smooth pursuit also often demonstrate abnormal 
suppression of the VOR.104,145 They exhibit catch-up saccades 
on head impulse testing.104,146 Lesions in the abducens nucleus 
or the pontine paramedian reticular formation (PPRF) and 
the ipsilateral MLF cause one-and-a-half syndrome, in which 
there is an ipsilateral horizontal gaze palsy and an INO.144,147 
Abduction of the contralateral eye is the only remaining 
horizontal eye movement.
Skew deviation is a vertical ocular misalignment and 
results from lesions in the pathways connecting the ves-
tibular nuclei in the medulla to the third and fourth nuclei 
in the midbrain.144 If the lesion is in the lower brainstem, 
the contralateral eye is hypertropic. Lesions in the pons and 
midbrain cause ipsilateral hypertropia. Patients will report 
vertical diplopia. The ocular tilt reaction is a skew deviation 
combined with head tilt (away from hypertropic eye) and 
conjugate ocular torsion.
The dorsal midbrain (Parinaud) syndrome and 
nuclear and fascicular cranial nerve lesions can occur 
in MS. In the former, lesions to the posterior midbrain 
cause supranuclear upgaze paresis, pupillary light-near 
  dissociation,   convergence-retraction nystagmus, and eyelid 
retraction.144,148,149 Of the cranial nerve syndromes, sixth nerve 
paresis is the most common.150–152 Nuclear lesions produce an 
ipsilateral gaze paresis, whereas fascicular lesions cause an 
ipsilateral lateral rectus palsy. Various presentations of third 
nerve palsies including partial fascicular, upper or lower divi-
sion, have been reported,150,153,154 whereas rare, isolated tro-
chlear (fourth) nerve paresis has been described in MS.155
Summary
Demyelinating lesions in MS cause characteristic afferent 
and efferent visual syndromes. Detection of these syndromes 
during ophthalmologic evaluation may lead to early diagno-
sis and treatment and potentially better outcomes for these 
patients. Vision loss and ocular motility deficits are associ-
ated with overall disability, and these disorders may be an 
indication of disease severity.
Careful attention to the neuro-ophthalmologic findings in MS 
not only reveals information about current disease burden, but also 
offers discrete measures of structure and function in an accessible 
part of the nervous system amenable to research and the testing of 
current and future therapies for this disabling disease.
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